Evidence map›Paper›PMID 40473401›Full record

ArticleGut2025

NLRP6 deficiency enhances macrophage-mediated phagocytosis via E-Syt1 to inhibit hepatocellular carcinoma progression.

Shuang Li, Yuchen Fu, Xiaodong Jia, Zherui Liu, Zhenwei Qian, Haoran Zha, Guanglin Lei, Lingxiang Yu, Xinfeng Zhang, Ting Zhang and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gut, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Shuang LiPeking University 302 Clinical Medical School, Peking University, Beijing, Beijing, China.
Yuchen FuKey Technology Research Center for Cell and Gene Industry, Shenzhen Cell Valley Biopharmaceuticals Co, Ltd, Shen Zhen, Guangdong, China.
Xiaodong JiaPeking University 302 Clinical Medical School, Peking University, Beijing, Beijing, China.ORCID 0000-0002-2145-6272
Zherui LiuPeking University 302 Clinical Medical School, Peking University, Beijing, Beijing, China.
Zhenwei QianPeking University 302 Clinical Medical School, Peking University, Beijing, Beijing, China.
Haoran ZhaPeking University 302 Clinical Medical School, Peking University, Beijing, Beijing, China.
Guanglin LeiPeking University 302 Clinical Medical School, Peking University, Beijing, Beijing, China.
Lingxiang YuPeking University 302 Clinical Medical School, Peking University, Beijing, Beijing, China.
Xinfeng ZhangPeking University 302 Clinical Medical School, Peking University, Beijing, Beijing, China.
Ting ZhangFlowCytology Laboratory, Beijing Gobroad Boren Hospital, Beijing, Beijing, China.
Tianyi ZhangPeking University 302 Clinical Medical School, Peking University, Beijing, Beijing, China.ORCID 0000-0001-9964-8840
Jie HanPeking University 302 Clinical Medical School, Peking University, Beijing, Beijing, China.
Yuanyuan ShiKey Technology Research Center for Cell and Gene Industry, Shenzhen Cell Valley Biopharmaceuticals Co, Ltd, Shen Zhen, Guangdong, China.
Rifaat SafadiHadassah Hebrew University Medical Center, Jerusalem, Israel.
Yinying LuPeking University 302 Clinical Medical School, Peking University, Beijing, Beijing, China luyinying1973@163.com.ORCID 0000-0002-7737-2334

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCurrent treatments with tyrosine kinase inhibitors and immune checkpoint inhibitors have limited efficacy for hepatocellular carcinoma (HCC) due to drug resistance. Emerging therapies such as chimeric antigen receptor T (CAR-T) and macrophage-based cell therapies are promising but need to be improved.

objectivesThis study investigates the role of macrophage NOD-like receptor family pyrin domain containing 6 (NLRP6) in HCC progression and its therapeutic potential.

designImmunofluorescence staining was performed in patient samples. Liver tumour models (autonomous, orthotopic, subcutaneous) were developed, and RNA sequencing, flow cytometry and immunohistochemistry were performed in wild-type,

resultsCD68 (a macrophage marker) and NLRP6 expression were detected in patient HCC tissues, and patients with lower macrophage NLRP6 expression had longer survival. Compared with their wild-type mice,

conclusionsNLRP6 promotes HCC progression by inhibiting macrophage infiltration and suppressing phagocytosis via the interaction between its PYD domain and E-Syt1's SMP domain. Transfer of

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsMacrophagesPhagocytosisAnimalsDisease ProgressionHumansMiceMice, KnockoutReceptors, Cell SurfaceNod-like receptor pyrin domain-containing protein 6, mouseReceptors, Cell SurfaceCANCERHEPATOCELLULAR CARCINOMALIVER IMMUNOLOGYMACROPHAGES

Identifiers

PMID40473401
PMCPMC12573374

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.